Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibody drugs targeting SARS-CoV-2: Time for a rethink?

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Jul 2024

Liang Likeng, Wang Bo, Zhang Qing, Zhang Shiwu, Zhang Sihe

Abstract excerpt

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) heavily burdens human health. Multiple neutralizing antibodies (nAbs) have been issued for emergency use or tested for treating infected patients in the clinic. However, SARS-CoV-2 variants of concern (VOC) carrying mutations reduce the effectiveness of nAbs by preventing neutralization....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Neutralizing
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to COVID-19

Share to COVID-19 Drug Treatment

Share to Mutation

Share to SARS-CoV-2

Source

Identifiers

PMID: 38861858
DOI: 10.1016/j.biopha.2024.116900

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibody drugs targeting SARS-CoV-2: Time for a rethink?PMID 38861858Read ↗

A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variantsSemantic proximity Read ↗

COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic StrategiesSemantic proximity Read ↗

Novel Antiviral Therapeutic Against SARS-CoV-2 and its Variants: Recent Developments and Future PerspectivesSemantic proximity Read ↗

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Semantic proximity Read ↗

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escapeSemantic proximity Read ↗

Broadening a SARS-CoV-1–neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolutionSemantic proximity Read ↗

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognitionSemantic proximity Read ↗

Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizersSemantic proximity Read ↗

Fast Restoration of a Broad-Spectrum SARS-Cov Therapeutic Antibody for SARS-Cov-2Semantic proximity Read ↗

An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2.Semantic proximity Read ↗

In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5 and BA.2.86Semantic proximity Read ↗

Updated Atlas of Currently Available Human Neutralizing Antibodies Against SARS-CoV-2 and Escape by Omicron Sub-Variants BA.2.12.1/BA.2.13/BA.4/BA.5Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.